Supplementary Table 3. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
dataset
posted on 2021-05-14, 09:24 authored by Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra, Daniela Scattolin, Stefano Indraccolo, Stefano Frega, Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, PierFranco Conte, Giulia Pasello|
Supplementary Table 3. Real world data on treatment outcomes in EGFR mutant NSCLC patients receiving osimertinib in second or further lines
Cox regression univariate and multivariate analysis including all covariates potentially impacting on overall survival. |
